Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients

J Antimicrob Chemother. 2003 Jan;51(1):135-9. doi: 10.1093/jac/dkg016.

Abstract

Objectives: To compare genotypic and phenotypic HIV-1 drug resistance assays.

Methods: Protease inhibitor (PI) susceptibility was phenotypically analysed in HIV-1 isolates and recombinant viruses expressing proteases from viral isolates. Two genotypic interpretation methods were carried out in parallel.

Results: Entirely concordant resistance levels were shown in 5/10 (50%) highly active anti-retroviral therapy (HAART)-experienced patients, whereas minor discrepancies were observed in the remaining five patients.

Conclusions: The four assays provide comparable results. The recombinant virus phenotypic assay may provide the most accurate evaluation of resistance; however, genotypic interpretation procedures are helpful for daily therapeutic decisions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiretroviral Therapy, Highly Active / statistics & numerical data
  • Drug Resistance, Viral / genetics*
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Infections / virology*
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics*
  • HIV-1 / isolation & purification
  • HeLa Cells
  • Humans
  • Phenotype*
  • Recombination, Genetic*

Substances

  • HIV Protease Inhibitors